BeOne Medicines (ONC) 44th Annual J.P. Morgan Healthcare Conference summary

Industry impact and innovation

• Significant progress in cancer treatment over the past decades, with new therapeutic modalities now central to care.

• Cancer survival rates have improved over 25 years, but significant unmet needs remain, especially in hard-to-treat cancers like pancreatic and liver cancer.

• Recent years have seen rapid innovation in oncology, including immuno-oncology, gene therapy, bispecifics, mRNA, cell therapy, radiopharmaceuticals, ADCs, degraders, covalent molecules, and siRNA.

• Commitment to relentless innovation and speed, highlighted by a focus on improving patient outcomes and survival rates.

• Despite progress, cancer continues to cause millions of deaths annually, underscoring the need for continued innovation.

Clinical data and therapeutic advancements

• BRUKINSA demonstrated superior long-term outcomes in CLL, with six-year PFS and OS rates of 74% and 84%, respectively.

• Only Brukinsa demonstrated progression-free survival (PFS) superiority to ibrutinib in head-to-head trials.

• New combinations, such as BRUKINSA plus sonrotoclax, show rapid, deep responses and may redefine fixed-duration therapy.

• First-in-class BTK CDAC offers promising results for relapsed CLL, with high response rates and broad mutation coverage.

• Multiple solid tumor programs achieved proof of concept, expanding the late-stage pipeline.

Financial performance and operational excellence

• Achieved significant product revenue growth in the first three quarters of 2025, with $3.8B in revenue, up 43% year-over-year.

• Reported GAAP profitability with diluted earnings per ADS of $1.96 and generated $562M in free cash flow.

• Generated over $350 million in free cash flow in Q3 and maintains over $4 billion in cash.

• Integrated in-house R&D and manufacturing enable rapid clinical development and global trial execution.

• Achieved record patient enrollment and regulatory filings, leveraging a global infrastructure.